Novo Nordisk Net Worth (Updated 2025).

Novo Nordisk, a name now synonymous with diabetes care, began its journey in 1923, founded by two Danish academics, August Krogh and Harald Jensen. Their initial focus was on insulin production, a groundbreaking hormone discovered just a decade prior, which revolutionized the treatment of diabetes. The company’s first product, a purified insulin derived from animal sources, was a significant advancement in the field and laid the foundation for its future success.

As the company grew, so did its reputation. In the 1940s, Novo Nordisk pioneered the use of pork insulin, which was more potent and less allergenic than the previously used beef insulin. This innovation further solidified the company’s position as a leader in diabetes care. The company’s commitment to research and development, coupled with its dedication to improving the lives of people with diabetes, has been the driving force behind its fame and success.

Novo Nordisk’s Current Net Worth (2025)

As of 2025, Novo Nordisk’s market capitalization stands at approximately $200 billion, making it one of the world’s most valuable pharmaceutical companies.

Career

Founded in 1923 by two Danish insulin researchers, Novo Nordisk has since grown into a global leader in diabetes care. Today, it employs over 43,000 people worldwide and operates in 79 countries.

Other Ventures

Beyond diabetes, Novo Nordisk is also involved in research and development of other chronic diseases like obesity and rare blood disorders. Additionally, they have a significant presence in biotechnology and healthcare innovation.

Assets

Novo Nordisk’s assets include extensive research and development facilities, global manufacturing sites, and a robust intellectual property portfolio. Their brand portfolio comprises several leading diabetes treatments, including Novolog, Levemir, and Victoza.

Annual Income

In 2020, Novo Nordisk reported a revenue of DKK 144.8 billion (approximately $23.7 billion). This was driven by strong sales of their diabetes and obesity care products, as well as contributions from their biopharmaceuticals business.

Frequently Asked Questions about  Novo Nordisk

Frequently Asked Questions: Novo Nordisk Net Worth

1. What is Novo Nordisk’s net worth?

Novo Nordisk’s net worth is estimated to be over $160 billion.

2. Who founded Novo Nordisk?

Novo Nordisk was founded by two Danish pharmacists, August Krogh and Marie Mannich, in 1923.

3. What does Novo Nordisk do?

Novo Nordisk is a global healthcare company that specializes in diabetes care, obesity, and other chronic diseases. They offer a wide range of products, including insulin, GLP-1 receptor agonists, and weight management solutions.

4. Where is Novo Nordisk headquartered?

Novo Nordisk’s global headquarters is located in Bagsværd, Denmark.

5. How many employees does Novo Nordisk have?

As of 2021, Novo Nordisk employed approximately 46,000 people worldwide.

6. What are some of Novo Nordisk’s most popular products?

Some of Novo Nordisk’s most popular products include insulin (Novolog, Novolin, Levemir, Tresiba, etc.) and GLP-1 receptor agonists (Victoza, Ozempic, Rybelsus, etc.).

7. How does Novo Nordisk contribute to society?

Novo Nordisk is committed to improving the lives of people with diabetes and other chronic diseases. They invest in research and development, provide access to healthcare in underserved communities, and support diabetes awareness and education initiatives.

8. What is Novo Nordisk’s stock symbol?

Novo Nordisk’s stock symbol on the New York Stock Exchange (NYSE) is NVO. On the Nasdaq Copenhagen, it is traded under the symbol NOVO B.

9. How does Novo Nordisk approach sustainability?

Novo Nordisk has a strong commitment to sustainability, focusing on areas such as climate change, water management, waste reduction, and responsible sourcing. They aim to be a carbon-neutral company by 2030.

10. What are some of Novo Nordisk’s competitors?

Some of Novo Nordisk’s main competitors in the diabetes care market include Eli Lilly and Company, Sanofi, and Merck & Co. They also compete with other pharmaceutical companies in the broader chronic diseases market.